Pharmaceuticals

The pharma giant's acquisition of Excellergy and its first-in-class Exl-111 could revolutionize treatment for millions with severe, debilitating allergies.

Agenus prepares a crucial update on its BOT+BAL immunotherapy, a potential breakthrough for cancers resistant to current treatments. What will they reveal?

Crinetics Pharmaceuticals aims to disrupt Brazil's acromegaly treatment with Palsonify, a once-daily pill challenging the standard of monthly injections.

With critical data due in 2026 and a leaner financial strategy, Zentalis is advancing its targeted therapy for a hard-to-treat ovarian cancer.

At a key investor conference, Renibus is pitching its two Phase 3 drugs, including one with a strategic pivot after a challenging trial result.

A promising oral therapy for a rare, aggressive lung cancer is now under review in Europe, offering a new option for patients with limited treatments.

As GLP-1 drug demand soars, Nordic Cold Chain Solutions launches a new lab to solve the complex puzzle of keeping these sensitive medicines safe.

A new report slams the FDA for blocking vital treatments with rising costs and denials, but the agency faces a complex reality of reform and internal pressure.

With $1B in funding and a new virtual cell model, Xaira Therapeutics hires a top dealmaker to turn its AI prowess into pharma partnerships.

A groundbreaking study of 78,000 people shows most with acne and psoriasis manage their conditions alone, outside the clinic. Here's what it means.

Top 200 firm Bober Markey Fedorovich hires Andrew Zinger, an expert with 20+ years of experience, to navigate an increasingly complex M&A landscape.

Nearly half of global C-suites plan US expansion, drawn by supply chains and capital, but face a surprising labyrinth of complex state and federal rules.

A new partnership sees a major Canadian hospital embrace RFID tech to automate its pharmacy, boosting efficiency and safeguarding patient care.

A novel drug targeting aging cells shows early success in treating psoriasis, eczema, and skin aging, heralding a new era in dermatology.

A new partnership will embed real-world cell therapy manufacturing into NJIT's graduate program, aiming to fill a critical skills gap in the biotech industry.

A key recommendation for the drug BIMZELX could soon give Quebec patients a powerful new weapon against the debilitating skin disease hidradenitis suppurativa.

A novel three-in-one antibody from CStone shows a 90% response rate in lung cancer and potent activity in 'cold tumors,' heralding a new era for immunotherapy.

PetaSight's acquisition of Babbage Insight aims to fix a broken system with an 'intelligent OS', tackling the 38% data discard rate in life sciences PMR.

A new lithium formula boosts brain delivery in a key trial, offering hope for safer, more effective treatments for Alzheimer's, bipolar disorder, and more.

A new RNA drug shows promise by reducing harmful belly fat while preserving muscle, but modest overall weight loss in early trials spooks investors.